MNG1259
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.415
- KRAS_SIGNALING_DN+0.409
- SPERMATOGENESIS+0.140
- COAGULATION+0.111
- MYOGENESIS+0.093
- APICAL_SURFACE-0.005
- ANGIOGENESIS-0.053
- KRAS_SIGNALING_UP-0.055
- ALLOGRAFT_REJECTION-0.069
- INFLAMMATORY_RESPONSE-0.076
Top 10 suppressed
- MYC_TARGETS_V1-0.615
- OXIDATIVE_PHOSPHORYLATION-0.588
- UNFOLDED_PROTEIN_RESPONSE-0.579
- E2F_TARGETS-0.566
- MTORC1_SIGNALING-0.565
- DNA_REPAIR-0.513
- G2M_CHECKPOINT-0.501
- MYC_TARGETS_V2-0.497
- PROTEIN_SECRETION-0.497
- ADIPOGENESIS-0.479
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG597 | — | — | 0.984 |
| 2 | 08e3d239-3d8a-4eee-9e08-ac2bcb3f2619 | — | — | 0.979 |
| 3 | SRR1366141 | GTEX | — | 0.974 |
| 4 | MNG598 | — | — | 0.974 |
| 5 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.972 |
| 6 | BS_23W9EPFE | Ganglioglioma | — | 0.971 |
| 7 | MNG1246 | — | — | 0.969 |
| 8 | MDT-AP-0706 | Med | Medulloblastoma | 0.969 |
| 9 | TCGA-DK-A1A7-01A-11R-A13Y-07 | — | — | 0.969 |
| 10 | msclc569389_S35.txt | — | cohortMD1 | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.415 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.409 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.111 | Binimetinib | — uncovered |
| MYOGENESIS | 0.093 | Inavolisib | — uncovered |